account_id none on file
legal_name Medicus Pharma Ltd.
ticker MDCX
cik 1997296
domain medicuspharma.com
linkedin_company_url https://www.linkedin.com/company/medicus-pharma-ltd%20%20%20%20
entry_point_account_id none on file
exchange Nasdaq
calls 0 filings 8 executives 1 family 0
why_nownone on file
callsnone on file
filings
If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations.
filing / Aug 12, 2026 / receipt
This increase was primarily due to an increase in consulting fees, salaries and wages with increased headcount at board and management level and fees, expenses related to business development and investor relations and stock-based compensation.
filing / Aug 12, 2026 / receipt
If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations.
filing / Aug 12, 2026 / receipt
This increase was primarily due to an increase in consulting fees, salaries and wages with increased headcount at board and management level and fees, expenses related to business development and investor relations and stock-based compensation.
filing / Aug 12, 2026 / receipt
If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations.
filing / May 14, 2026 / receipt
This increase was primarily due to an increase in consulting fees, salaries and wages with increased headcount at board and management level and fees, expenses related to business development and investor relations and stock-based compensation.
filing / May 14, 2026 / receipt
If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations.
filing / May 14, 2026 / receipt
This increase was primarily due to an increase in consulting fees, salaries and wages with increased headcount at board and management level and fees, expenses related to business development and investor relations and stock-based compensation.
filing / May 14, 2026 / receipt
executives
| Andrew Smith | Chief Operating Officer | - | receipt |
familynone on file
upcoming
| 2026-11-13 | earnings call | scheduled | ir |
changes
| 2025-06-23 | Chief Operating Officer, appointed | sec_8k |
mcp_package_hint
slug medicus-pharma-ltd
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$